Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

144.69 -1.91 (-1.30%)
Streaming Delayed Price Updated: 3:36 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,262,104
Open 145.93
Bid (Size) 144.68 (2)
Ask (Size) 144.71 (2)
Prev. Close 146.60
Today's Range 143.44 - 145.93
52wk Range 133.05 - 175.91
Shares Outstanding N/A
Dividend Yield 3.59%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
The 3 Most Undervalued Penny Stocks to Buy in February 2023
Here are three penny stocks in emerging sectors that look to be undervalued relative to the consensus price target of analysts. 
Via InvestorPlace

Performance

YTD
-10.89%
-10.89%
1 Month
-10.89%
-10.89%
3 Month
+0.12%
+0.12%
6 Month
+2.47%
+2.47%
1 Year
+5.61%
+5.61%

More News

Read More
2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade
Via The Motley Fool
3 Ultra-Profitable Businesses to Invest in for the Long Haul
Via The Motley Fool
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline
Via Benzinga
2 of the Best Dividend Stocks to Own in 2023
Via The Motley Fool
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
2 Top Passive-Income Stocks to Own in 2023
Via The Motley Fool
AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.
Via The Motley Fool
3 Juicy Dividend Stocks in Warren Buffett's Secret Portfolio to Buy in February
Via The Motley Fool
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Via Investor's Business Daily
These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts
Via Benzinga
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Via Talk Markets
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Via The Motley Fool
S&P Global, AbbVie, And This Big 3 Automaker On CNBC's 'Final Trades'
Via Benzinga
7 Dividend Stocks to Buy Now or You’ll Be Kicking Yourself Later
Via InvestorPlace
5 Cheapest Health Care Stocks You Should Think About
Via Benzinga
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Via InvestorPlace
3 Reasons to Buy AbbVie and 2 Reasons Not to Buy
Via The Motley Fool
Want Safety and Growth in 2023? Try These Dividend Stocks.
Via The Motley Fool
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Via MarketBeat
Charles River Laboratories, AbbVie, Star Bulk Carriers And This Big Bank Are CNBC's 'Final Trades'
Via Benzinga
7 Stocks Every Smart Investor Should Own in 2023
Via InvestorPlace
3 Unstoppable Stocks to Keep Buying in 2023
Via The Motley Fool
AbbVie Stock: Dividend King ABBV Overview
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.